Andelyn Biosciences’ Post

13 CGT approvals coming in 2024, See the full list here 👇 5 therapies are focused on CAR-T, 8 gene therapy (5 ex vivo, 3 in vivo). ➡️ The indications range from leukaemia and multiple myeloma to genetic disorders like metachromatic leukodystrophy and haemophilia B. The routes of administration vary, with some being one-time injections, surgical grafts, or multi-dose intradermal injections. Exciting stuff. (Source: CVS Health Report and I had the pleasure collaborating with Jeffrey C. Martin, Ph.D. on this one). 𝐇𝐨𝐰 𝐦𝐚𝐧𝐲 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐝𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐰𝐢𝐥𝐥 𝐠𝐚𝐢𝐧 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥? I'm intrigued to hear what factors you see as critical for their success... #celltherapy #genetherapy #CGTweekly #biotech

Financing the promise of cell and gene therapy is the focus of this newest blog from Munich Re Ventures. Read to learn how these new therapies can serve as a forcing function to better align incentives in the healthcare ecosystem: https://lnkd.in/dtKXRFga #MunichReVentures

Just thinking about this topic today as we're about to see a number of these CGT approvals come through. These are some of the things that I think about when taking into consideration the question: "what factors are critical to the success of these products" 1. Patient base & ability to engage with the patients; what does the doctor and insurance engagement look like 2. Efficacy of the product beyond what the FDA requires; is it accessible to the doctors/patient based on cost, what does availability look like from a manufacturing and distribution point, and what % beneficial impact does it have on a broad spectrum of patients 3. Financial backing / ability to scale and control manufacturing; cell therapy products are highly susceptible to damage in the MFG stage and transport to the patient site 4. Profit margin perceived prior to launch; what will the initial revenue stream look like, and how does this scale with time. Does this product open up new opportunities in different subsets of patients? not necessarily in that order... I hope that all of these products are successful as I can see a huge leap in patient care with these new an innovative therapies in the coming years!

The development of transformative cell and gene therapies (CGTs) requires bounds of time, expertise, and financial resources — ensuring that patients can truly reap the benefits of your innovation is essential. Unlock the full potential of your product and make the most of your investments by following this step-by-step guide to CGT commercialization. Download now https://lnkd.in/ecn9SSNq

Struggling to simplify a complex message? Motion graphics can help! Take a look at our latest project with biotech company Sarepta Therapeutics, where we explain Limb-Girdle Muscle Dystrophy Gene Therapy. 🚀 #motiongraphics #chicagovideo #videoproduction #videoproductioncompany #seo #onlinemarketing #bottlerocket #sarepta #videomarketing #lgmdawareness #biotech #pharmaindustry #medicalvideo #musculardystrophyresearch

The development of transformative cell and gene therapies (CGTs) requires bounds of time, expertise, and financial resources — ensuring that patients can truly reap the benefits of your innovation is essential. Unlock the full potential of your product and make the most of your investments by following this step-by-step guide to CGT commercialization. Download now https://lnkd.in/ecn9SSNq

The development of transformative cell and gene therapies (CGTs) requires bounds of time, expertise, and financial resources — ensuring that patients can truly reap the benefits of your innovation is essential. Unlock the full potential of your product and make the most of your investments by following this step-by-step guide to CGT commercialization. Download now https://lnkd.in/ecn9SSNq

ICYMI: The Cell and Gene Therapy Catapult (CGT) has released its 2024 Annual Review 🦠🔬. This report highlights significant milestones made by the CGT Catapult and the UK’s advanced therapy medicinal products (ATMP) industry. Key achievements from the past year include: ➡️ 79 companies collaborated with on ATMP innovation (56% of which are UK SMEs) ➡️ £656m in financing raised by their UK collaborators (including £453m by its collaborators in Stevenage) ➡️ 11 companies supported that are conducting clinical trials As part of the Innovate UK Catapult Network, the CGT Catapult plays a crucial role in driving the growth of next-generation therapies that can transform patient care and contribute to national economic growth. Read the report here: https://lnkd.in/eJetPtsy...

Engaging discussion on the challenges, emerging trends, and key value drivers shaping the Cell & Gene Therapy (C&GT) space, as well as the potential growth opportunities in Europe at Advanced Therapies Europe 2024. At Invivo Partners, we’re confident that the C&GT field will continue to advance, with promising expansions into new indications, the exploration of novel cell types, and the development of cutting-edge technologies to tackle the challenges ahead. #ATE24

Come check out our next workshop focusing on Cell and Gene therapy!